AYTU.NASDAQAytu Biopharma, INC
Form 4: Aytu BioPharma CFO Ryan Selhorn Reports Stock Transactions
Sentiment:
SEC Form 4 Filing
Ryan Selhorn, CFO of Aytu BioPharma, reports the vesting and disposal of restricted stock units.
Summary
- On February 5, 2025, Ryan J. Selhorn, the Chief Financial Officer of Aytu BioPharma, reported a transaction involving restricted stock units (RSUs).
- The transaction involved the vesting of 105 RSUs, each representing a contingent right to receive one share of Aytu BioPharma's common stock.
- These RSUs were granted on February 5, 2022, and vested quarterly beginning February 5, 2023, and ending February 5, 2025.
- Following the transaction, Selhorn disposed of 16,000 common shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock transactions by a company executive, indicating a neutral sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/05/2022 | RSUs were granted |
| 02/05/2023 | RSUs vesting quarterly began |
| 02/05/2025 | RSUs vesting quarterly ended and transaction date |
| 03/03/2025 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.